Everett, K.D. et al. J. Bacteriol. 177(4):877-882, Feb. 1995.* |
Bertrand et al., “L'Ofloxacine (RU 43280) etude clinique” Path Biol. 35:629-633 (1987) abstract only. |
Drancourt et al., “Oral rifampin plus ofloxacin for treatment of staphylococcus-infected orthopedic implants” Antimicrobial Agents and Chemotherapy 37:1214-1218 (199f3). |
Freidank et al., “In vitro susceptibilities of Chlamydia pneumoniae isolates from german patients and synergistic activity of antibiotic combinations” Antimicrobial Agents and Chemotherapy 43:1808-1810 (1999). |
Lay-Schmitt et al., “Evidence for infection with Chlamydia pneumoniae in subgroup of patients with multiple sclerosis” Annals of Neurology 47:652-655 (2000). |
Sriram et al., “Multiple sclerosis associated with Chlamydia pneumoniae infection of the CNS” Neurology 50:571-572 (1998). |
Sriram et al., “C. pneumoniae infection of the CNS in patients with relapsing remitting MS” Neurology 52:A558 (1999). |
Sriram et al., “Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis” Annals of Neurology 46:6-14(1999). |
Yao et al., “Association between C. pneumoniae and MS,” Journal of Neuroimmunology 90:70 (1998). |
Yao et al., “CNS infection with C. pneumoniae in MS,” Neurology 50:A423-A424 (1998). |
Yao et al., “Reactivity of oligoclonal bands seen in CSF to C. pneumoniae antigens in patients with Multiple Sclerosis,” Neurology 52:A559 (1999). |
Coles, A.M. et al. FEMS Microbiology Letters 106:193-200, 1993.* |
Khan, M.A. et al. J. Antimicrobial Chemotherapy 37:677-685, Apr. 1996.* |
Beatty, W.L. et al. Microbiological Reviews 58(4):686-699, Dec. 1994.* |
Neeper, I.D. et al. Infection and Immunity 58(7):2042-2047, Jul. 1990.* |
Gaydos, C.A. et al. Clinical Infectious Diseases 17:718-23, 1993.* |
Hackstadt, T. et al. J. Bacteriology 161(1):25-31, Jan. 1985.* |
Tjhie, H.T.J. et al. J. Microbiological Methods 18:137-150, 1993.* |
Kaltenboeck, B. et al. J. Bacteriology 175(2):487-502, Jan. 1993.* |
Carter, M.W. et al. J. General Microbiology 137:465-475, 1991.* |
Hammerschlag, M.R. et al. Clinical Infectious Diseases 14:178-182, 1992.* |
Heinonen, Pentti K., et al., “A Comparison of Ciprofloxacin with Doxycycline plus Metronidazole in the Treatment of Acute Pelvic Inflammatory Disease”, Scand. J. Infect. Dis. Suppl., 60: 66-73 (1989). |
Burchell, H.J., et al., “Efficacy of Different Antibiotics in the Treatment of Pelvic Inflammatory Disease”, SAMJ., 72: 248-249 (Aug. 15, 1987). |
Paavonen, J., et al., “Factors Predicting Abnormal Hysterosal-pingographic Findings in Patients Treated for Acute Pelvic Inflammatory Disease”, Int. J. Gynaecol. Obstet., 23: 171-175 (1985). |
Miettinen, A., et al., “The Effect of Ciprofloxacin and Doxycycline Plus Metronidazole on Lower Genital Tract Flora in Patients with Proven Pelvic Inflammatory Disease”, Arch. Gynecol. Obstet., 249: 95-101 (1991). |
Judlin, P., et al., “Etude Comparative Des Associations Ofloxacine + Amoxicilline-Acide Clavulanique Versus Doxycycline + Amoxicilline-Acide Clavulanique Dans Le Traitement Des Infections Génitales Hautes A Chlamydia Trachomatis”, J. Gynecol. Obstet. Biol. Reprod., 24: 253-259 (1995). |
Henry-Suchet, J., “Traitement Des Infections Utéro-Annexielles Sexuellement Transmises (IUAST) Sauf Syphilis Et Herpés”, Méd. Mal. Infect., 24: 379-387 (1994). |
Joly-Guillou, M.L., et al., “Bactéries Isolées En 1994-1995 Au Cours Des Infections Gynécologiques Hautes Et Des Uréthrites Masculines”, La Presse Médicale 2-9 Mars 25, (8): 342-348 (1996). |
Orfila, J. and Haider, F., “Comparative Study Of The In Vitro Activity Of Lomefloxacin Versus Lomefloxacin Combined With Metronidazole Versus Lomefloxacin In Combination With Amoxicillin/Clavulanic Acid Against Chlamydia Trachmatis”, Intern. J. Antimicro. Agents, 2: 11-14 (1992). |
Witte, E.H., et al., “A Comparison Of Pefloxacin/Metronidazole And Doxycycline/Metronidazole in the Treatment of Laparoscopically Confirmed Acute Pelvic Inflammatory Disease”, Eur. J. Obstet. Gynec. and Repro. Bio., 50: 153-158 (1993). |